Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation

Novartis

Status and phase: Completed; Phase 3

Conditions: Kidney Transplantation

Treatments: Drug: FTY720

Study type: Interventional

Funder types: Industry

Identifiers

NCT00098735

CFTY720A2302

Details and patient eligibility

About

In patients who receive an organ transplant, their body considers this organ as foreign and attempts to destroy it. This is called rejection. All patients who receive an organ transplant, will take a combination of anti-rejection medications. These medications prevent the new organ from being rejected from the body. FTY720 is a new compound that helps prevent organ rejection.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• First kidney transplantation
• Male and female patients
• Between 18 and 65 years old

Exclusion criteria

• Patient in need of multi-organ transplant
• Patients with history of cardiac arrest
• Patients with any past or present malignancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)